NCT02528188: A reported trial by Pfizer
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02528188 |
|---|---|
| Title | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 21, 2015 |
| Completion date | Oct. 5, 2018 |
| Required reporting date | Oct. 5, 2019, midnight |
| Actual reporting date | Oct. 4, 2019 |
| Date last checked at ClinicalTrials.gov | Sept. 11, 2025 |
| Days late | None |